SynthesisThe Journal of infection2020
How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.
Synthesis in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 1 synthesis or guideline pooled it.
- COVID-19 FAQs in paediatric and congenital cardiology: AEPC position paper.Cardiology in the young · 2021Guideline
- Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis.Arthritis research & therapy · 2020Trial
- COVID-19 clinical outcomes in pediatrics: Comparison between immunocompromised and immunocompetent patients in ColombiaBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Successful Management of Severe COVID-19 in a Kidney Transplant Recipient Safe Co-Administered Tacrolimus and Ensitrelvir: A Case Report.Reports (MDPI) · 2026Article
- Alcohol-associated liver disease is associated with less adverse outcomes compared to nonalcohol-associated liver disease in patients with COVID-19.Alcohol, clinical & experimental research · 2025Observational
- Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Clinical Outcomes of Pediatric Cancer Patients with COVID-19: A Cross-Sectional Study.International journal of hematology-oncology and stem cell research · 2024Article
- Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Comparative evaluation of RT-PCR and antigen-based rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 detection: performance, variant specificity, and clinical implications.Microbiology spectrum · 2024Article
- SARS-CoV-2 Seroprevalence in Children under 5 Years Old-A Regional Seroepidemiological Study.Medicina (Kaunas, Lithuania) · 2024Article
- Vaccination protects against acute respiratory distress syndrome (ARDS) in hospitalized patients with COVID-19.Clinical and experimental medicine · 2024Article
- Outcomes of Patients Undergoing Major Surgery for Cancer with COVID-19 in the Postoperative Period.Indian journal of surgical oncology · 2023Article
- Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines.Tuberkuloz ve toraks · 2023Article
- COVID-19 in immunocompromised children: comparison of SARS-CoV-2 viral load dynamics between the first and third waves.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection.Pediatric blood & cancer · 2023Article
- Observational
- The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic.Frontiers in medicine · 2023Article
- The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report.Iranian journal of medical sciences · 2023Article
- COVID-19 in children and adolescents with neuroimmunological disorders.Clinics (Sao Paulo, Brazil) · 2023Article
- Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort.Scientific reports · 2022Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSARS-CoV-2 infection has now a global resonance. Data on how COVID-19 is affecting immunocompromised patients are however few. With our study we aimed to systematically review the current knowledge on SARS-CoV-2 cases in children and adults with immunosuppression, to evaluate outcomes in this special population.
methodsA systematic review of literature was carried out to identify relevant articles, searching the EMBASE, Medline, and Google Scholar databases. Studies reporting data on pre-defined outcomes and related to immunosuppressed adults and children with SARS-CoV-2 were included.
resultsSixteen relevant articles were identified with 110 immunosuppressed patients, mostly presenting cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe course, but not necessarily with a bad prognosis. Our data show that both children and adults with immunosuppression seem to have a favorable disease course, as compared to the general population.
conclusionImmunosuppressed patients with COVID-19 seem to be few in relation to the overall figures, and to present a favorable outcome as compared to other comorbidities. This might be explained by a hypothetical protective role of a weaker immune response, determining a milder disease presentation and thus underdiagnosis. Nevertheless, surveillance on this special population should be encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.